ArticleBMC pulmonary medicine2025
Telehealth in sarcoidosis: a scoping review.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSarcoidosis is an inflammatory disease that causes functional and physical limitations in patients, negatively impacting their quality of life. Telehealth can provide a solution to improve healthcare services for these patients, regardless of their social and economic status. This research explores the various telehealth technologies and their applications for patients with sarcoidosis. MATERIAL AND
methodsThis scoping review was conducted in 2024 with a comprehensive search in PubMed, Web of Science, Scopus, and ProQuest databases. Following screening and duplicate removal, relevant data were extracted and analyzed.
resultsOut of 821 studies, only 6 studies met the inclusion criteria. The findings showed that mHealth technologies have good acceptance among patients and healthcare providers in managing sarcoidosis symptoms, such as fatigue, stress, and physical activity levels, and improving quality of life. Also, activity tracker technology, alone or in combination with other remote monitoring tools, increases exercise performance, reduces fatigue, and allows for continuous monitoring of the disease status. Hence, it has the potential to be integrated into long-term care programs for patients with sarcoidosis. In addition, telerehabilitation technology could be an acceptable option for patients, but its effectiveness in improving exercise capacity and quality of life in patients with sarcoidosis requires further investigation.
conclusionmHealth and activity tracker technology showed promising results in improving sarcoidosis management and increasing patients' motivation and adherence to treatment, but further studies are required to assess the effectiveness of telerehabilitation. Overall, telehealth has significant potential to improve the care of sarcoidosis patients, but further research is needed to evaluate the effectiveness of these technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.